Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nelfinavir · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Nelfinavir mesylate | DRUG | - |
| Levocarnitine | DRUG | - |
| Adefovir dipivoxil | DRUG | - |
| Saquinavir | DRUG | - |
| Lamivudine | DRUG | - |
| Stavudine | DRUG | - |
| Zidovudine | DRUG | - |
Inclusion Criteria Patients must have: * Laboratory diagnosis of HIV infection (positive HIV antibody test confirmed by Western blot, p24 antigen assay, HIV-1 RNA, or HIV-1 culture). * An HIV-1 RNA plasma titer \>= 5000 copies/ml within 14-21 days prior to the baseline visit. * CD4 cell count \>= ...
Top 20 of 28 competitors
Nelfinavir is an investigational small molecule being studied for the treatment of HIV Infections. It is currently in Phase 2 clinical development. The drug is being evaluated in combination with other antiretroviral therapies, including protease inhibitors and nucleoside reverse transcriptase inhibitors, for HIV-infected patients.
Nelfinavir is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GILD. The company is conducting clinical research to evaluate the safety and efficacy of Nelfinavir in patients with HIV Infections.
Nelfinavir is in Phase 2 clinical development for the treatment of HIV Infections. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 clinical trial has been completed to evaluate its safety and efficacy in HIV-infected patients.
Nelfinavir has been studied in one completed Phase 2 clinical trial, identified as NCT00002184. This was a stratified, randomized, double-blind, multi-center study that enrolled 120 HIV-infected patients in the United States and Puerto Rico. The trial evaluated Nelfinavir in triple combination therapies with protease inhibitors and nucleoside reverse transcriptase inhibitors.
No, Nelfinavir is not the same as Adefovir Dipivoxil. The completed clinical trial NCT00002184 evaluated Adefovir Dipivoxil at two dose levels in combination with protease inhibitors and nucleoside reverse transcriptase inhibitors for HIV treatment. Nelfinavir is a separate investigational drug being developed by Gilead Sciences for HIV Infections.